Predicting the Drug Interaction Potential of AMG 853, a Dual Antagonist of the D-Prostanoid and Chemoattractant Receptor-Homologous Molecule Expressed on T Helper 2 Cells Receptors

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Drug Metabolism And Disposition

• Publication date

  2012-08-28

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.112.047928PMID 22930276
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast.

  2012influential reference
• Optimization of phenylacetic acid derivatives for CRTH2 and DP selective antagonism.

  2012cited by this paper
• A randomized, double‐blind, placebo‐controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma

  2012cited by this paper
• The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.

  2012influential reference
• Evaluation of CYP2C8 Inhibition In Vitro: Utility of Montelukast as a Selective CYP2C8 Probe Substrate

  2011cited by this paper
• Studies to Further Investigate the Inhibition of Human Liver Microsomal CYP2C8 by the Acyl-β-Glucuronide of Gemfibrozil

  2011cited by this paper
• Utility of Intersystem Extrapolation Factors in Early Reaction Phenotyping and the Quantitative Extrapolation of Human Liver Microsomal Intrinsic Clearance Using Recombinant Cytochromes P450

  2011cited by this paper
• Are Circulating Metabolites Important in Drug–Drug Interactions?: Quantitative Analysis of Risk Prediction and Inhibitory Potency

  2011cited by this paper
• Reevaluation of the Microsomal Metabolism of Montelukast: Major Contribution by CYP2C8 at Clinically Relevant Concentrations

  2011cited by this paper
• Discovery of AMG 853, a CRTH2 and DP Dual Antagonist.

  2011cited by this paper
• Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast

  2010cited by this paper
• Identification of Novel Substrates for Human Cytochrome P450 2J2

  2010cited by this paper
• Guideline on the Investigation of Drug Interactions

  2010cited by this paper
• DP2 receptor antagonists in development

  2010cited by this paper
• Application of cytochrome P450 drug interaction screening in drug discovery.

  2010cited by this paper
• Modulation of UDP-glucuronosyltransferase activity by protein-protein association

  2010cited by this paper
• Drug-drug interactions: is there an optimal way to study them?

  2010cited by this paper
• Single-Dose, First-in-Human Study of AMG 853: Pharmacokinetics, Pharmacodynamics, and Safety in Healthy Adults

  2010cited by this paper
• Drug interactions evaluation: an integrated part of risk assessment of therapeutics.

  2010cited by this paper
• Interaction of Cytochrome P450 3A4 and UDP-Glucuronosyltransferase 2B7: Evidence for Protein-Protein Association and Possible Involvement of CYP3A4 J-Helix in the Interaction

  2009cited by this paper
• Discovery and optimization of CRTH2 and DP dual antagonists.

  2009cited by this paper
• Benzylic oxidation of gemfibrozil-1-O-beta-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition.

  2009cited by this paper
• Predicting Drug–Drug Interactions: An FDA Perspective

  2009influential reference
• Qualitative Analysis of the Role of Metabolites in Inhibitory Drug‐Drug Interactions: literature evaluation based on the Metabolism and Transport Drug Interaction Database

  2009cited by this paper
• New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process

  2008cited by this paper
• Prediction of CYP-mediated drug interactions in vivo using in vitro data.

  2008cited by this paper
• Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling

  2007cited by this paper
• The effect of MK-0524, a prostaglandin D2 receptor antagonist, on prostaglandin D2-induced nasal airway obstruction in healthy volunteers

  2007influential reference
• Suppression of Niacin‐induced Vasodilation with an Antagonist to Prostaglandin D2 Receptor Subtype 1

  2007cited by this paper
• Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases

  2007cited by this paper
• GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS

  2006cited by this paper
• Variability of CYP2J2 Expression in Human Fetal Tissues

  2006cited by this paper
• THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”

  2006cited by this paper
• Coimmunoprecipitation of UDP-Glucuronosyltransferase Isoforms and Cytochrome P450 3A4

  2005cited by this paper
• Validated assays for human cytochrome P450 activities.

  2004cited by this paper
• Role of prostanoid DP receptor variants in susceptibility to asthma.

  2004influential reference
• Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible.

  2004cited by this paper
• Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors

  2004cited by this paper
• An Orally Bioavailable Small Molecule Antagonist of CRTH2, Ramatroban (BAY u3405), Inhibits Prostaglandin D2-Induced Eosinophil Migration in Vitro

  2003cited by this paper
• Cytochrome P450 Reaction Phenotyping

  2003cited by this paper
• An orally-bioavailable small molecule antagonist of CRTH 2 , ramatroban ( BAY u 3405 ) , inhibits PGD 2-induced eosinophil migration in vitro

  2002cited by this paper
• Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole.

  2002cited by this paper
• Expression and Regulation of Xenobiotic-Metabolizing Cytochrome P450 (CYP) Enzymes in Human Lung

  2002cited by this paper
• Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes.

  2002cited by this paper
• Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751.

  2001influential reference
• Prostaglandin D2 Selectively Induces Chemotaxis in T Helper Type 2 Cells, Eosinophils, and Basophils via Seven-Transmembrane Receptor Crth2

  2001cited by this paper
• Molecular Cloning and Expression of CYP2J2, a Human Cytochrome P450 Arachidonic Acid Epoxygenase Highly Expressed in Heart (*)

  1996cited by this paper
• CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance.

  1996cited by this paper
• Clinical Pharmacokinetics of Paclitaxel

  1994cited by this paper
• Liquid chromatographic determination of gemfibrozil and its metabolite in plasma.

  1986cited by this paper
• Gas chromatographic determination of gemfibrozil and its metabolites in plasma and urine.

  1984cited by this paper
• The Metabolism of Gemfibrozil

  1976cited by this paper

• Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions

  2016influential citation
• Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs

  2014cites this paper